Compare Range Resources Corporation Common Stock (RRC) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Range Resources Corporation Common Stock vs Revolution Medicines Inc. Common Stock — how do they compare? Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B), while Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 4.1× Range Resources Corporation Common Stock's market cap, and Range Resources Corporation Common Stock pays a 0.94% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Range Resources Corporation Common Stock for 0 Days and Revolution Medicines Inc. Common Stock for 2 Days on average.
| RRC | RVMD | |
|---|---|---|
Market Cap | $9.93B | $40.39B |
Volume | 2,413,752 | 2,941,009 |
Sector | Energy | Health |
52-Week High | $47.65 | $221.15 |
52-Week Low | $33.43 | $49.56 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $10.94B | $37.09B |
Dividend Yield | 0.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Range Resources Corporation Common Stock
Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
